Trial Profile
Host Mechanisms Involved in Achieving SVR Using Grazoprevir and Elbasvir in Treatment of Chronic Hepatitis C in Patients With CKD Before and After Renal Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 26 Oct 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 Planned End Date changed from 31 Dec 2021 to 1 Jun 2022.
- 01 Sep 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.